BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) today announced an updated schedule for the release of information related to certain of its ongoing clinical trials. RegeneRx currently estimates that it will report on its Phase II pressure ulcer trial evaluating RGN-137 by mid-January 2009; on its Phase II venous stasis ulcer trial, also evaluating RGN-137, in February 2009; and on its Phase I parenteral trial evaluating RGN-352 in March 2009. RGN-137 is a topical gel formulation of Tß4 being developed for dermal wound healing and RGN-352 is an injectable formulation of Tß4 being developed for internal indications such as acute myocardial infarction (“heart attack”).
